Pfizer discontinues Phase III clinical trial of Sutent in CRPC

An announcement yesterday has made it clear that sunitinib malate (Sutent) is unlikely to ever show significant clinical activity in the management of patients with advanced, castration-resistant prostate cancer (CRPC) after initial chemotherapy. … READ MORE …

Prostate cancer news reports: Tuesday, September 1, 2009

Today’s news reports contain items on:

  • Racial disparities in 10-year survival, even in specialized clinical trials
  • Sunitinib + docetaxel in treatment of CRPC
  • Docetaxel + ABT-751 in treatment of CRPC … READ MORE …

Prostate cancer news reports: Thursday, June 18, 2009

Articles addressed in this report deal with:

  • The reactions of men to a diagnosis of prostate cancer
  • Current and potential uses of dynamic, contrast-enhanced MRI in patient evaluation
  • How much does benign prostatic tissue affect PSA levels after radical prostatectomy?
  • The potential of sunitinib and vandetanib  in treatment of CRPC … READ MORE …

Today’s prostate cancer news: Wednesday, October 8

Other than the PCA3 report, additional news today includes:

  • A new review on the combination of EBRT and brachytherapy in localized disease
  • Long-term follow-up data on the use of HIFU at a major German center
  • Early trial data on use of Sutent and Rapamume in men who have failed docetaxel
  • The possible role of pituitary gland surgery in very late stage disease … READ MORE …